“Test the Taste”, a Special Event for PKU Patients: Enjoying Food Thanks to APR Innovative Supplementation
APR Applied Pharma Research s.a (APR), the Swiss developer of science driven and patent protected healthcare products, is pleased to share the success of a special event, “Test the taste”, addressed to Phenylketonuria (PKU) patients and organized with the purpose of allowing them to test the company innovative Phenylalanine (Phe)-free medical food for PKU management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180712005363/en/
Thumbs up from patients and families on APR's innovative medical food for PKU (Photo: APR)
The initiative, promoted by the APMMC, the Italian patients association of inherited metabolic diseases with the unconditioned support of APR, aimed at gathering genuine feedbacks from PKU patients and their families on the company innovative medical food palatability in a friendly and relaxed setting - a Sunday lunch.
During the lunch, a well-known chef prepared, under medical supervision, a full menu suitable for a PKU diet, made of four dishes - from appetizer to dessert, each of them including APR Phe-free amino-acids (AA) supplementation.
After each course, patients and caregivers, who did not receive any information about the company innovation, were asked to assess the supplemented food just enjoyed (under medical guidance) as per texture, odor, taste and after-taste by filling out a brief questionnaire. For a complete evaluation, appetizer was served twice, with and without APR’s Phe-free AA mix, to allow the audience to better grab the differences.
Responses from both patients and families are extremely positive: no remarkable differences were reported in terms of odor and taste after sampling the appetizer with or without the AA mix.
According to the guests, APR innovative Phe-free supplementation did not affect the overall food taste and odor as the opinions expressed on the dishes served mostly referred to either the flavor or the texture of the ingredients regardless of the AA mix. The most noticeable feedback is the one regarding the aftertaste of the AA mix, which, as reported by PKU patients, could impact negatively their food experience: APR Phe-free AA mixture was markedly appreciated.
“At last thanks to APR’s new AA mix we have the chance to enjoy a delicious lunch without worrying about odor, taste and aftertaste of the supplementation.” said a patient who participated to the initiative “Food palatability was really great and we are eager to test this innovative AA mix a variety of recipes! We hope to find soon APR’s AA mix available as it can help us as patients to achieve a lasting and rewarding compliance to the compulsory dietary regimen”.
“As father of a PKU teenager and having gone through the troubles of a strict long-life dietetic treatment, we are very proud to offer to patients a new perspective of quality of life. Our dream is to make a real difference for those who live and deal with PKU.” said Paolo Galfetti, CEO of APR.
APR’s innovative and patented Physiomimic Technology® is able to remarkably mask the naturally unpleasant taste and the odor of some amino acids, offering a considerably palatable medical food, which can be easily accepted by patients, thus supporting their compliance and impacting positively their quality of life.
On the other side, as shown in a recent kinetic study, APR’s advanced formulation of AAs, by providing amino acids in more physiological manner (mimicking that of dietary proteins), has the very encouraging potential of contributing to maintain Phe levels within the recommended ranges, with less prominent fluctuations of Phe over time, thanks to a prolonged release of AAs in the gut.
Further preclinical studies as well as clinical evidences are underway to reinforce the scientific profile of the innovative medical food.
APR will present officially its new range of Phe-free medical food for PKU dietary management, as well as new original scientific data, at the next Annual Symposium of the SSIEM (Society for the Study of Inborn Errors of Metabolism) on September 4th-7th in Athens, which will be the occasion for attendees to get to know APR’s innovation and the patented technology behind it.
About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/
APR Applied Pharma Research s.a.:
Paolo Galfetti, Chief Executive Officer
+41 91 6957020
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Corsair Infrastructure Partners Announces Transaction Involving DP World Australia23.1.2019 04:35 | Pressemelding
Corsair Infrastructure Partners (“CIP”), the global infrastructure investment business of Corsair Capital (“Corsair”), today announced that Gateway Infrastructure Investments (“Gateway”), an investment fund managed by CIP, as well as several other financial investors, have entered into agreements to sell their entire stakes in DP World Australia (Holding) Pty Ltd (“DPWA”) to DP World and new investment funds managed by CIP. The closing of the transaction is subject to regulatory approvals. As a result of this transaction, DP World, the original corporate parent of DPWA, will hold a majority stake in the company, alongside a substantial minority investment by CIP-managed funds. Hari R. Rajan, Managing Director of Corsair and Head of CIP, said, “We are pleased to have achieved the exit of Gateway’s investment in DPWA, while maintaining our strong relationship with DP World through our continued management of a large investment in the company. We believe this new shareholder structure wil
Yokogawa Joins Global 100 Most Sustainable Corporations in the World Index23.1.2019 04:00 | Pressemelding
Yokogawa Electric Corporation (TOKYO:6841) announces that it has been included in the 2019 Global 100 Most Sustainable Corporations in the World Index (Global 100). This is Yokogawa’s first time on the Global 100, one of the world's leading sustainability indices. Now in its 15th year, the 2019 Global 100 was disclosed in Davos on January 22nd by Corporate Knights, a Canadian media and research company focused on clean capitalism, to coincide with the World Economic Forum. To determine the 2019 ranking, Corporate Knights undertook a rigorous analysis of more than 7,500 companies with US$1B+ in revenues against global industry peers on a suite of up to 21 quantitative key performance indicators, weighted to reflect each industry’s impact profile. Yokogawa was ranked in the top 25% in both the clean revenues* and innovation capacity categories. In its core industrial automation and control business, Yokogawa works with customers in the energy, chemical, iron and steel, water, and other i
V-CAT to Begin a New Type of Crowdfunding, Using Digital Currency23.1.2019 00:00 | Pressemelding
V-CAT Vietnam will develop a new type of crowdfunding services that uses digital currency. A platform that uses the JC-coin digital currency will be built, and all data involved in transactions will be safely protected with leading-edge blockchain technology. Any user with JC-coins can exchange any physical or digital assets they might own on the platform for more JC-coins. This will provide the funding needed to develop revolutionary new products and services, together with users worldwide, and will enable new investments in all kinds of different businesses. V-CAT is proceeding with development of the MALLLESS platform in advance of an April 2019 launch of services. The goal is to host 10 million users worldwide by 2020. What makes MALLLESS unique is that businesses and individuals can take advantage of the point-transfer transaction model website and the proprietary wallet mechanism, both of which enable any selling of new or used goods, or of intangibles. There is also conversions
Prominent Trade Consulting Firm in South Korea Switches to Rimini Street Support for Its Oracle Database22.1.2019 23:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that EC21, a leading export marketing and trade consulting firm in Korea, has switched to Rimini Street support for its Oracle Database software. By switching to Rimini Street, EC21 is able to dramatically reduce the total cost of maintenance of its Oracle Database by approximately 75 percent, and improved productivity within its IT department as resources can be reallocated to more strategic projects across the organization. EC21 can also maintain its robust, stable database platform for a minimum of 15 years from the time the company moved to Rimini Street, avoiding any unnecessary upgrades just to retain full support from the vendor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005104/en/ Prominent Trade Consulting Fir
IFF to Release Fourth Quarter and Full Year 2018 Results February 1322.1.2019 21:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its fourth quarter and full year 2018 earnings results following the market close on Wednesday, February 13, 2019. The management team will host a live webcast on Thursday, February 14, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what i
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 201922.1.2019 21:05 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 3826138 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, February 6, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (int